ControlRad Systems is Granted Second U.S. Patent

PHILADELPHIA, PA., June 20, 2014 – ControlRad Systems, Inc., a medical device company developing innovative products to dramatically reduce radiation exposure and risk for patients and physicians performing fluoroscopic procedures, has been granted a second patent from the U.S. Patent and Trademark Office for the company’s radiation control and minimization. The company has a broad portfolio of additional patents filed globally.

The company’s products are designed to allow physicians to identify a customized region of interest based on their attention during a procedure, either via pointing or via the automated detection of their gaze. In response to the attention of the physician, the system directs a dynamic collimator, or shutter, to instantly provide full dose radiation in the region of interest, while providing a substantially lower dose of radiation to the peripheral field of view. The automated system capitalizes on the fact that the human eye has limited ability to see fine detail in the peripheral field of view, thus a substantially reduced dose of radiation can provide sufficient image quality in those areas without compromising perceived image utility.

U.S. Patent Number 8,754,388 was awarded to Dr. Guez, co-founder and President of ControlRad. It was assigned exclusively to ControlRad Systems, Inc., on June 17, 2014.

About ControlRad

ControlRad is a privately-held medical technology company developing innovative products that dramatically reduce the lifetime risk of radiation exposure from fluoroscopically guided interventional procedures (FGIP) for patients and healthcare professionals. These products are designed to improve safety without compromising image quality or workflow. This is accomplished with an integrated set of proprietary components which optimize the X-ray beam to deliver optimal image quality in the clinically-relevant region of focus of the physician while maintaining appropriate resolution in the periphery. ControlRad is headquartered in Philadelphia and has engineering development facilities in Kfar Saba, Israel. For more information, visit